TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:31
Black Diamond Therapeutics Inc. ( BDTX ) https://www.blackdiamondtherapeutics.com
2.30USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-24.09%
BDTX
SPY
32.66%
-56.11%
BDTX
SPY
108.59%
BDTX
0.00%
SPY
302.52%
BDTX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
125.45
35.76
0.38
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.72
25.63
1.29
-45.18
0.00
-0.46
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-413.69
-1.76
-399.94
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-122.58
-56.19
0.00
Other Earnings and Cash Flow Stats:
Black Diamond Therapeutics Inc. ( BDTX ) Net Income TTM ($MM) is -73.10
Black Diamond Therapeutics Inc. ( BDTX ) Operating Income TTM ($MM) is -81.36
Black Diamond Therapeutics Inc. ( BDTX ) Owners' Earnings Annual ($MM) is 0.00
Black Diamond Therapeutics Inc. ( BDTX ) Current Price to Owners' Earnings ratio is 0.00
Black Diamond Therapeutics Inc. ( BDTX ) EBITDA TTM ($MM) is -81.02
Black Diamond Therapeutics Inc. ( BDTX ) EBITDA Margin is -399.94%
Capital Allocation:
Black Diamond Therapeutics Inc. ( BDTX ) has paid 0.00 dividends per share and bought back -5.564801 million shares in the past 12 months
Black Diamond Therapeutics Inc. ( BDTX ) has reduced its debt by 3.043 million USD in the last 12 months
Capital Structure:
Black Diamond Therapeutics Inc. ( BDTX ) Interest-bearing Debt ($MM) as of last quarter is 23
Black Diamond Therapeutics Inc. ( BDTX ) Annual Working Capital Investments ($MM) are -5
Black Diamond Therapeutics Inc. ( BDTX ) Book Value ($MM) as of last quarter is 97
Black Diamond Therapeutics Inc. ( BDTX ) Debt/Capital as of last quarter is 23%
Other Balance Sheet Stats:
Black Diamond Therapeutics Inc. ( BDTX ) has 23 million in cash on hand as of last quarter
Black Diamond Therapeutics Inc. ( BDTX ) has 20 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Black Diamond Therapeutics Inc. ( BDTX ) has 56 common shares outstanding as of last quarter
Black Diamond Therapeutics Inc. ( BDTX ) has 0 million USD of preferred stock value
Academic Scores:
Black Diamond Therapeutics Inc. ( BDTX ) Altman Z-Score is -3.84 as of last quarter
Black Diamond Therapeutics Inc. ( BDTX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Black Diamond Therapeutics Inc. ( BDTX ) largest shareholder is owning shares at 0.00 ($MM) value
Versant Venture Capital VI, L.P.(an insider) Sold 221600 shares of Black Diamond Therapeutics Inc. ( BDTX ) for the amount of $1400556.32 on 2024-08-28
2.29% of Black Diamond Therapeutics Inc. ( BDTX ) is held by insiders, and 98.71% is held by institutions
Black Diamond Therapeutics Inc. ( BDTX ) went public on 2020-01-30
Other Black Diamond Therapeutics Inc. ( BDTX ) financial metrics:
FCF:-90.72
Unlevered Free Cash Flow:0.00
EPS:-1.10
Operating Margin:-413.69
Gross Profit Margin:-1.76
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-63.87
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Black Diamond Therapeutics Inc. ( BDTX ) :
Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.